MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

AMG 925 HCl

CAS No. : 1401034-19-2

MCE 國(guó)際站：AMG 925 HCl

產(chǎn)品活性：AMG 925 HCl 是一種有效的選擇性的 FLT3/CDK4 雙重抑制劑，IC₅₀ 分別為 2±1 nM 和 3±1 nM。

研究領(lǐng)域：Protein Tyrosine Kinase/RTK??|??Cell Cycle/DNA Damage

作用靶點(diǎn)：FLT3??|??CDK

In Vitro: AMG 925 also inhibits CDK6, CDK2, and CDK1 in kinase assays with IC₅₀s of 8±2 nM, 375±150 nM, 1.90±0.51 μM, respectively. A fair overall kinase selectivity of AMG 925 is as determined by KinomScan against a panel of 442 various kinases. Cellular selectivity (on-target vs. off-target activity) of AMG 925 is about 50-fold as evaluated by comparison of its growth-inhibiting activity in RB-positive (RB⁺) and RB-negative (RB^-) non- acute myeloid leukemia (AML) cancer cell lines. AMG 925 potently inhibits growth of AML cell lines MOLM13 (FLT3-ITD; IC₅₀=19 μM) and Mv4-11 (FLT3-ITD; IC₅₀=18 μM).

In Vivo: MOLM13 tumor-bearing mice are dosed twice daily by oral administration 6 hours apart with 12.5, 25, or 37.5 mg/kg AMG 925. Tumors are then harvested 3, 9, 12, and 24 hours after the first dose, and analyzed for levels of P-STAT5 and P-RB. Maximum inhibition of P-STAT5 and P-RB is achieved at 6 and 12 hours respectively at the 37.5 mg/kg dose of AMG 925. Interestingly, a rebound of P-STAT5 at 24 hours is observed, possibly as a result of compensational feedback. The pharmacodynamic responses of P-STAT5 and P-RB inhibition correlated with plasma concentrations of AMG 925. AMG 925 inhibits AML xenograft tumor growth by 96% to 99% without significant body weight loss. The antitumor activity of AMG 925 correlates with the inhibition of STAT5 and retinoblastoma protein (RB) phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, respectively. In addition, AMG 925 is also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and Sorafenib).

相關(guān)產(chǎn)品：Sorafenib??|??Palbociclib??|??Abemaciclib??|??Ro-3306??|??Ribociclib??|??Cabozantinib??|??Gilteritinib??|??Dinaciclib??|??GSK3326595??|??Quizartinib??|??Flavopiridol??|??(R)-Roscovitine??|??THZ1??|??AZD4573??|??THZ531??|??Pacritinib??|??SR-4835??|??Kenpaullone??|??R406??|??SY-5609??|??Wogonin??|??GSK 3 Inhibitor IX??|??SNS-032??|??Fostamatinib??|??Crenolanib??|??Toyocamycin

熱門產(chǎn)品線：重組蛋白? |? 藥物篩選? |? 天然產(chǎn)物? |? 熒光染料? |? PROTAC? |? 同位素標(biāo)記物

Trending products：Recombinant Proteins? |? Bioactive Screening Libraries? |? Natural Products? |? Dye Reagents? |? PROTAC? |? Isotope-Labeled Compounds

品牌介紹:
????MCE (MedChemExpress) 擁有200 多種全球獨(dú)家化合物庫(kù)，我們致力于為全球科研客戶提供前沿最全的高品質(zhì)小分子活性化合物；
????50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號(hào)通路及疾病領(lǐng)域；
????產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目；
????提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測(cè)分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
????設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系；
????提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告，確保產(chǎn)品的高純度、高品質(zhì)；
????產(chǎn)品的生物活性多經(jīng)各國(guó)客戶實(shí)驗(yàn)驗(yàn)證；
????Nature, Cell, Science 等多種頂級(jí)期刊及制藥專利收錄了MCE客戶的科研成果；
????專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展，為您提供全球最新的活性化合物；
????與世界各大制藥公司及知名科研機(jī)構(gòu)建立了長(zhǎng)期的合作。